中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 6
Jun.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(6): 1301-1309

Association between liver fibrosis staging and colorectal space-occupying lesions in metabolic associated fatty liver disease

DOI: 10.12449/JCH260611
  • 1.

    Department of Gastroenterology，The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital，Jinan 250014，China

  • 2.

    Graduate School，Shandong First Medical University （Shandong Academy of Medical Sciences），Jinan 250117，China

Research funding:

Shandong Provincial Medical Association Clinical Research Fund-Qilu Special Project (YXH2022ZX02113)

More Information
  • Corresponding author: LI Kun， 19223926920@163.com （ORCID： 0009-0000-1252-5187）
  • Received Date: 2025-12-09
  • Accepted Date: 2026-02-12
  • Published Date: 2026-06-25
    Abstract
  •   Objective  To investigate whether there exists an independent association beyond shared risk factors between colorectal space-occupying lesions and metabolic associated fatty liver disease （MAFLD）， and to provide new ideas for early identification of colorectal space-occupying lesions in the MAFLD population.  Methods  A retrospective analysis was performed for 12 252 patients who were hospitalized in The First Affiliated Hospital of Shandong First Medical University （Shandong Provincial Qianfoshan Hospital） and underwent both colonoscopy and abdominal imaging （abdominal ultrasound， magnetic resonance imaging， or computed tomography） from September 1， 2018 to August 31， 2023. According to colonoscopy findings， the patients were divided into colorectal space-occupying lesion group with 6 545 patients and non-colorectal space-occupying lesion group with 5 707 patients. Baseline data were compared between the two groups. The univariate and multivariate Logistic regression analyses were used to identify influencing factors for colorectal space-occupying lesions， and further analysis was performed to investigate the association of MAFLD and liver fibrosis （assessed by fibrosis-4 ［FIB-4］， nonalcoholic fatty liver disease fibrosis score ［NFS］， and aspartate aminotransferase-to-platelet ratio index） with colorectal space-occupying lesions. The Mann-Whitney U test was used for comparison of continuous data with skewed distribution between groups， and the chi-square test or the Fisher’s exact test was used for comparison of categorical data between groups.  Results  The univariate analysis showed that compared with the non-colorectal space-occupying lesion group， the colorectal space-occupying lesion group had significantly higher age （Z=-95.628， P<0.001）， proportion of male patients （χ2=406.910， P<0.001）， body weight （Z=-24.928， P<0.001）， body mass index （BMI） （Z=-21.367， P<0.001）， diastolic blood pressure （Z=-15.527， P<0.001）， systolic blood pressure （Z=-16.965， P<0.001）， proportion of patients with history of coronary heart disease （χ2 =28.112， P<0.001）/hypertension （χ2 =152.993， P<0.001）/diabetes （χ2 =52.175， P<0.001）/cerebral infarction （χ2 =14.097， P<0.001）， white blood cell count （WBC） （Z=-12.801， P<0.001）， hemoglobin （HGB） （Z=-19.258， P<0.001）， aspartate aminotransferase （Z=-6.673， P=0.001）， alanine aminotransferase （Z=-10.375， P<0.001）， alkaline phosphatase （Z=-10.496， P<0.001）， gamma-glutamyl transpeptidase （GGT） （Z=-18.893， P<0.001）， blood urea nitrogen （Z=-13.291， P<0.001）， creatinine （Z=-16.798， P<0.001）， uric acid （Z=-16.822， P<0.001）， triglyceride （Z=-10.186， P<0.001）， and fasting blood glucose （Z=-15.761， P<0.001）. The multivariate Logistic regression analysis showed that age （odds ratio ［OR］=1.052， 95% confidence interval ［CI］： 1.045 — 1.057， P<0.001）， sex （OR=0.523， 95%CI： 0.466 — 0.587， P<0.001）， BMI （OR=1.031， 95%CI： 1.018 — 1.046， P<0.001）， history of hypertension （OR=1.140， 95%CI： 1.019 — 1.276， P=0.022）， WBC （OR=1.057， 95%CI： 1.028 — 1.087， P<0.001）， GGT （OR=1.001， 95%CI： 1.000 — 1.002， P=0.021）， Alb （OR=0.982， 95%CI： 0.969 — 0.995， P=0.008）， and HGB （OR=1.004， 95%CI： 1.001 — 1.008， P=0.019） were independent influencing factors for colorectal space-occupying lesions. In the MAFLD population， after adjustment for age， sex， BMI， history of hypertension， WBC， HGB， GGT， and Alb， intermediate-to-high risk of advanced liver fibrosis assessed by FIB-4 and NFS was still an influencing factor for colorectal space-occupying lesions （FIB-4： OR=1.457， 95%CI： 1.176 — 1.810， P<0.05； NFS： OR=1.499， 95%CI： 1.244 — 1.809， P<0.05）. Liver fibrosis degree based on FIB-4 was not significantly associated with the pathological type， location， size， or number of colorectal space-occupying lesions （all P>0.05）. While intermediate-to-high risk of advanced liver fibrosis based on NFS was not associated with pathological type， location， or size， it might be associated with the number of lesions （χ2=9.770， P<0.05）.  Conclusion  Age， sex， BMI， history of hypertension， WBC， HGB， GGT， and Alb are independent influencing factors for colorectal space-occupying lesions. Intermediate-to-high risk of advanced liver fibrosis assessed by FIB-4 or NFS is independently associated with colorectal space-occupying lesions， and liver fibrosis assessed by NFS might be associated with the increase in the number of lesions.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    LOU TW, YANG RX, FAN JG. The global burden of fatty liver disease: The major impact of China[J]. Hepatobiliary Surg Nutr, 2024, 13( 1): 119- 123. DOI: 10.21037/hbsn-23-556.
    [2]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of metabolic dysfunction-associated(non-alcoholic) fatty liver disease(version 2024)[J]. J Pract Hepatol, 2024, 27( 4): 494- 510. DOI: 10.3760/cma.j.cn501113-20240327-00163.

    中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27( 4): 494- 510. DOI: 10.3760/cma.j.cn501113-20240327-00163. Chinese Society
    [3]
    SANNA C, ROSSO C, MARIETTI M, et al. Non-alcoholic fatty liver disease and extra-hepatic cancers[J]. Int J Mol Sci, 2016, 17( 5): 717. DOI: 10.3390/ijms17050717.
    [4]
    MANTOVANI A, PETRACCA G, BEATRICE G, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: A meta-analysis of observational cohort studies[J]. Gut, 2022, 71( 4): 778- 788. DOI: 10.1136/gutjnl-2021-324191.
    [5]
    YE SJ, LIU Y, ZHANG T, et al. Analysis of the correlation between non-alcoholic fatty liver disease and the risk of colorectal neoplasms[J]. Front Pharmacol, 2022, 13: 1068432. DOI: 10.3389/fphar.2022.1068432.
    [6]
    SIEGEL RL, MILLER KD, WAGLE NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73( 1): 17- 48. DOI: 10.3322/caac.21763.
    [7]
    BUDHATHOKI S, IWASAKI M, YAMAJI T, et al. Dietary heterocyclic amine intake, NAT2 genetic polymorphism, and colorectal adenoma risk: The colorectal adenoma study in Tokyo[J]. Cancer Epidemiol Biomarkers Prev, 2015, 24( 3): 613- 620. DOI: 10.1158/1055-9965.EPI-14-1051.
    [8]
    ZAUBER AG, WINAWER SJ, O’BRIEN MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths[J]. N Engl J Med, 2012, 366( 8): 687- 696. DOI: 10.1056/NEJMoa1100370.
    [9]
    ANSTEE QM, CASTERA L, LOOMBA R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future[J]. J Hepatol, 2022, 76( 6): 1362- 1378. DOI: 10.1016/j.jhep.2022.03.026.
    [10]
    QIU YS, XIE WN, LI CY, et al. Diagnostic value of ultrasound elastography combined with APRI in liver fibrosis of patients with metabolic dysfunction-associated fatty liver disease[J]. Clin Misdiagn Misther, 2025, 38( 24): 62- 68. DOI: 10.3969/j.issn.1002-3429.2025.24.010.

    邱燕生, 谢维宁, 李彩妍, 等. 超声弹性成像联合APRI对代谢相关脂肪性肝病肝纤维化的诊断价值[J]. 临床误诊误治, 2025, 38( 24): 62- 68. DOI: 10.3969/j.issn.1002-3429.2025.24.010.
    [11]
    NAGTEGAAL ID, ODZE RD, KLIMSTRA D, et al. The 2019 WHO classification of tumours of the digestive system[J]. Histopathology, 2020, 76( 2): 182- 188. DOI: 10.1111/his.13975.
    [12]
    STRUM WB. Colorectal adenomas[J]. N Engl J Med, 2016, 374( 11): 1065- 1075. DOI: 10.1056/nejmra1513581.
    [13]
    NISHIZAWA T, YOSHIDA S, TOYOSHIMA A, et al. Endoscopic diagnosis for colorectal sessile serrated lesions[J]. World J Gastroenterol, 2021, 27( 13): 1321- 1329. DOI: 10.3748/wjg.v27.i13.1321.
    [14]
    TROVATO A, TURSHUDZHYAN A, TADROS M. Serrated lesions: A challenging enemy[J]. World J Gastroenterol, 2021, 27( 34): 5625- 5629. DOI: 10.3748/wjg.v27.i34.5625.
    [15]
    SEO JY, BAE JH, KWAK MS, et al. The risk of colorectal adenoma in nonalcoholic or metabolic-associated fatty liver disease[J]. Biomedicines, 2021, 9( 10): 1401. DOI: 10.3390/biomedicines9101401.
    [16]
    LI Y, LIU SS, GAO YQ, et al. Association between NAFLD and risk of colorectal adenoma in Chinese Han population[J]. J Clin Transl Hepatol, 2019, 7( 2): 99- 105. DOI: 10.14218/JCTH.2019.00010.
    [17]
    TOUZIN NT, BUSH KNV, WILLIAMS CD, et al. Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease[J]. Therap Adv Gastroenterol, 2011, 4( 3): 169- 176. DOI: 10.1177/1756283X11402118.
    [18]
    LEE J, VALI Y, BOURSIER J, et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review[J]. Liver Int, 2021, 41( 2): 261- 270. DOI: 10.1111/liv.14669.
    [19]
    TINCOPA MA, LOOMBA R. Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. Lancet Gastroenterol Hepatol, 2023, 8( 7): 660- 670. DOI: 10.1016/S2468-1253(23)00066-3.
    [20]
    MANTOVANI A, DAURIZ M, BYRNE CD, et al. Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: A systematic review and meta-analysis[J]. Metabolism, 2018, 87: 1- 12. DOI: 10.1016/j.metabol.2018.06.004.
    [21]
    GIOVANNUCCI E. Metabolic syndrome, hyperinsulinemia, and colon cancer: A review[J]. Am J Clin Nutr, 2007, 86( 3): s836- s842. DOI: 10.1093/ajcn/86.3.836S.
    [22]
    KIM S, KEKU TO, MARTIN C, et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas[J]. Cancer Res, 2008, 68( 1): 323- 328. DOI: 10.1158/0008-5472.CAN-07-2924.
    [23]
    BOURSIER J, MUELLER O, BARRET M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota[J]. Hepatology, 2016, 63( 3): 764- 775. DOI: 10.1002/hep.28356.
    [24]
    KHOV N. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2014, 20( 22): 6821. DOI: 10.3748/wjg.v20.i22.6821.
    [25]
    BORA A, ALPTEKIN C, YAVUZ A, et al. Assessment of liver volume with computed tomography and comparison of findings with ultrasonography[J]. Abdom Imaging, 2014, 39( 6): 1153- 1161. DOI: 10.1007/s00261-014-0146-5.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (44) PDF downloads(16) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return